Fecal transplants for autism deliver success in clinical trials

A two-year clinical trial by Arizona State University researchers found that fecal transplants reduced autism symptoms by up to 45%, with benefits improving over time rather than diminishing. The treatment works by increasing gut microbial diversity in autistic children, who typically have significantly lower bacterial diversity than non-autistic children, and addresses the gastrointestinal issues that affect 30-50% of people with autism. The research is now advancing to Phase 3 human trials.